 phase II studi combin carboplatin ifosfamid metastat small cell lung carcinoma phase II studi combin activ agent small cell lung carcinoma sclc carboplatin ifosfamid thirti patient men women median age year studi twelv patient metastat site metastat site median perform statu chemotherapi CT regimen cours studi carboplatin ifosfamid mesna week patient evalu complet remiss CR partial remiss PR object respons rate median respons time month median surviv time month rang month bone marrow toxic grade iii patient grade IV patient carboplatin ifosfamid combin cross-resist doxorubicin etoposid regimen patient combin cisplatin ifosfamid carboplatin regimen ifosfamid carboplatin combin inclus non-cross-resist CT schedul